All articles by Urtė Fultinavičiūtė

Urtė Fultinavičiūtė is a healthcare reporter for Clinical Trials Arena. Urtė's coverage focuses on clinical data management and clinical strategy. Urtė holds an MA in International Journalism from City, University of London.

Urtė Fultinavičiūtė


Revive enrols first patient into psilocybin trial for substance use disorder

The Phase I/II trial will investigate psilocybin-assisted psychotherapy with topline results expected in Q3 2023.

Ionis and AstraZeneca report additional positive topline data from a Phase III ATTRv-PN trial

Eplontersen demonstrated statistically significant and clinically meaningful changes in patients with ATTRv-PN at 66 weeks of treatment.

DTRA aims to connect the DCT community by launching a virtual meetup channel platform

The Decentralized Trials Research Alliance (DTRA) will offer its members virtual meetups and communication channels to share their experiences with DCTs.

Managed access programmes: expanding clinical development plans for patients in need

Clinical Trials Arena explores key considerations on regulations, geographical footprint, and stakeholder involvement to implement a successful managed access programme (MAP).

Sustainability and tech at the forefront of clinical trial supply chains

An expert panel discussed upcoming trends at the Clinical Trial Supply Europe 2023 conference on 15–16 March.

FDA guidance agenda: what is CDER cooking for clinical trials?

Experts share their expectations for the FDA’s clinical development guidance documents that are planned for publication in 2023.

eConsent in clinical trials: what’s new and what’s yet to come?

An expert panel at Medidata’s NEXT London conference discussed the latest on adoption of electronic consent.

Acumen reveals late-stage clinical trial plans in early Alzheimer’s disease

President and CEO Daniel O’Connell previews the design of an upcoming trial investigating ACU193, a monoclonal antibody for AD.

A year of Russia’s war in Ukraine: who is winning the battle on clinical trials?

Despite clinical trials being heavily impacted in both Ukraine and Russia, each may face a different future for their clinical industry.

Inflammatory bowel disease trials: addressing the challenge of declining enrolment

Experienced IBD researchers explore possible solutions to patient recruitment challenges as hundreds of trials await initiation.